Malignant mesothelioma treated with immune checkpoint inhibitors with or without cancer vaccine (the NIPU-study) Background
Malignant pleural mesothelioma (MPM) is a disease with poor prognosis and few treatment options after first line chemotherapy. Treatment with the immune checkpoint inhibitors ipilimumab and nivolumab (ipi/nivo) combined has shown promising responses, but many patients do not respond and improvements are still called for. UV1-vaccination against telomerase increases T-cell infiltration in tumours, and may be added to the ipi/nivo combination for synergistic effect. The vaccine is tested in other cancer types and is safe and has shown promising results.